MSH6 and pituitary tumor: Publications focusing on the mechanisms of acquiring TMZ resistance in pituitary tumors have shown that one patient presented progression and resistance to TMZ with loss of MSH6 protein immunoexpression during treatment (54) and in another publication, a patient with germline MSH2 mutation was unresponsive to TMZ therapy (55).